Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work

The COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has stretched national testing capacities to breaking points in almost all countries of the world. The need to rapidly screen vast numbers of a country’s population in order to control the spread of the infection is paramount. However, the l...

Full description

Bibliographic Details
Published in:Diagnostics
Main Authors: Ray K. Iles, Raminta Zmuidinaite, Jason K. Iles, George Carnell, Alex Sampson, Jonathan L. Heeney
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Subjects:
Online Access:https://www.mdpi.com/2075-4418/10/10/746
_version_ 1851843048802091008
author Ray K. Iles
Raminta Zmuidinaite
Jason K. Iles
George Carnell
Alex Sampson
Jonathan L. Heeney
author_facet Ray K. Iles
Raminta Zmuidinaite
Jason K. Iles
George Carnell
Alex Sampson
Jonathan L. Heeney
author_sort Ray K. Iles
collection DOAJ
container_title Diagnostics
description The COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has stretched national testing capacities to breaking points in almost all countries of the world. The need to rapidly screen vast numbers of a country’s population in order to control the spread of the infection is paramount. However, the logistical requirement for reagent supply (and associated cost) of RT-PCR based testing (the current front-line test) have been hugely problematic. Mass spectrometry-based methods using swab and gargle samples have been reported with promise, but have not approached the task from a systematic analysis of the entire diagnostic process. Here, the pipeline from sample processing, the biological characteristics of the pathogen in human biofluid, the downstream bio- and physical-chemistry and the all-important data processing with clinical interpretation and reporting, are carefully compiled into a single high-throughput and reproducible rapid process. Utilizing MALDI-ToF mass spectrometric detection to viral envelope glycoproteins in a systems biology-multidisciplinary team approach, we have achieved a multifaceted clinical MALDI ToF MS screening test, primarily (but not limited to) SARS-CoV-2, with direct application to other future epidemics/pandemics that may arise. The clinical information generated not only includes SARS-CoV-2 coronavirus detection–(Spike protein fragments S1, S2b, S2a peaks), but other respiratory viral infections detected as well as an assessment of generalised oral upper respiratory immune response (elevated total Ig light chain peak) and a measure of the viral immune response (elevated intensity of IgA heavy chain peak). The advantages of the method include; (1) ease of sampling, (2) speed of analysis, and much reduced cost of testing. These features reveal the diagnostic utility of MALDI-ToF mass spectrometry as a powerful and economically attractive global solution
format Article
id doaj-art-e72688b2a3f94fb79e0349e4d87e44e0
institution Directory of Open Access Journals
issn 2075-4418
language English
publishDate 2020-09-01
publisher MDPI AG
record_format Article
spelling doaj-art-e72688b2a3f94fb79e0349e4d87e44e02025-08-19T22:27:33ZengMDPI AGDiagnostics2075-44182020-09-01101074610.3390/diagnostics10100746Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team WorkRay K. Iles0Raminta Zmuidinaite1Jason K. Iles2George Carnell3Alex Sampson4Jonathan L. Heeney5MAPSciences the iLAB, Stannard Way, Bedford MK44 3RZ, UKMAPSciences the iLAB, Stannard Way, Bedford MK44 3RZ, UKMAPSciences the iLAB, Stannard Way, Bedford MK44 3RZ, UKLaboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UKLaboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UKLaboratory of Viral Zoonotics, Department of Veterinary Medicine, Cambridge University, Madingley Road, Cambridge CB3 0ES, UKThe COVID-19 pandemic caused by the SARS-CoV-2 coronavirus has stretched national testing capacities to breaking points in almost all countries of the world. The need to rapidly screen vast numbers of a country’s population in order to control the spread of the infection is paramount. However, the logistical requirement for reagent supply (and associated cost) of RT-PCR based testing (the current front-line test) have been hugely problematic. Mass spectrometry-based methods using swab and gargle samples have been reported with promise, but have not approached the task from a systematic analysis of the entire diagnostic process. Here, the pipeline from sample processing, the biological characteristics of the pathogen in human biofluid, the downstream bio- and physical-chemistry and the all-important data processing with clinical interpretation and reporting, are carefully compiled into a single high-throughput and reproducible rapid process. Utilizing MALDI-ToF mass spectrometric detection to viral envelope glycoproteins in a systems biology-multidisciplinary team approach, we have achieved a multifaceted clinical MALDI ToF MS screening test, primarily (but not limited to) SARS-CoV-2, with direct application to other future epidemics/pandemics that may arise. The clinical information generated not only includes SARS-CoV-2 coronavirus detection–(Spike protein fragments S1, S2b, S2a peaks), but other respiratory viral infections detected as well as an assessment of generalised oral upper respiratory immune response (elevated total Ig light chain peak) and a measure of the viral immune response (elevated intensity of IgA heavy chain peak). The advantages of the method include; (1) ease of sampling, (2) speed of analysis, and much reduced cost of testing. These features reveal the diagnostic utility of MALDI-ToF mass spectrometry as a powerful and economically attractive global solutionhttps://www.mdpi.com/2075-4418/10/10/746biosecurityCOVID-19SARS-CoV-2screeningdiagnostic testMALDI-ToF MS
spellingShingle Ray K. Iles
Raminta Zmuidinaite
Jason K. Iles
George Carnell
Alex Sampson
Jonathan L. Heeney
Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
biosecurity
COVID-19
SARS-CoV-2
screening
diagnostic test
MALDI-ToF MS
title Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
title_full Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
title_fullStr Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
title_full_unstemmed Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
title_short Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
title_sort development of a clinical maldi tof mass spectrometry assay for sars cov 2 rational design and multi disciplinary team work
topic biosecurity
COVID-19
SARS-CoV-2
screening
diagnostic test
MALDI-ToF MS
url https://www.mdpi.com/2075-4418/10/10/746
work_keys_str_mv AT raykiles developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork
AT ramintazmuidinaite developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork
AT jasonkiles developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork
AT georgecarnell developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork
AT alexsampson developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork
AT jonathanlheeney developmentofaclinicalmalditofmassspectrometryassayforsarscov2rationaldesignandmultidisciplinaryteamwork